Novel therapeutic strategies for treatment of liver cancer

Vimalavathini R., Marthiyana Begum M, Suganthi A, Vimalrai T, Kavimani S.


Liver cancer is the most common type of solid tumor with poor prognosis. Various environmental, genetic and epigenetic factors including aberrant molecular signaling pathways play a significant role in pathogenesis of liver cancer. Targeting these molecular pathways has paved the way for evolution of molecular targeted drugs. Liver being less immunogenic strategies to improve immunosurveillance evasion by cancer cells has been addressed using immunotherapy. Research on novel therapeutic strategies such as immunotherapy, molecular targeted therapy, gene therapy is ongoing. This review aims to discuss current trends and recent developments in the field of liver cancer therapy.


liver cancer, immunotherapy, targeted therapy

Full Text:



Pascual S, Herrea I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-38.

Terry K, Copur MS. Molecular targeted therapy of hepatocellular carcinoma. Journal of Cancer Therapy, 2013;4:426-39.

Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenteral 2015; 21(36): 10314-26.

Li S, Yang F, Ren X. Immunotherapy for hepatocellular carcinoma. Drug Discoveries and Therapeutics.2015; 9(5):363-71.

Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006 ;25(27):3866-84.

Llovet JM, Bruix JD. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):131227.

Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess. 2010;14 Suppl 1:17-21.

Shin JW, Chung Y. Molecular targeted therapy for hepatocellular carcinoma: Current and future. World J Gastroenterol, 2013; 19(37): 6144-55.

Wang C, Wey K, Mo L, Chang K, Lin R, Kuo J. Current trends and recent advances in diagnosis, therapy and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16(9):3595-604.

Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol 2015;21(28): 8478-91.

Gong XL, Qin S. Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(29):658294.

Chen C, Wang G. Mechanism of HCC and challenges and opportunities for molecular targeted therapy. World J Hepatol.2015; 7(15): 1964-70.

Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma, J Hepatol. 2006;45(6):868-78.

Aravalli R, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes (Basel). 2017;8(2). doi: 10.3390/genes8020076.

Willimsky G, Protzer U, Knolle P, Heikenwalder M. Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key? Oncotarget 2013;4(8):1117-8.

Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. Journal of Cancer 2011, 2:363-8.

Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials. Oncology 2017;92(suppl 1):5062.

Hernndez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. World J Gastroenterol. 2006;12(38):608597.


Copyright (c) 2017 International Journal of Pharmacological Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.